ArticlePloS one2026
Transcriptomic associations and biomarkers in ANCA‑associated Glomerulonephritis and IgG4‑related Disease: A bioinformatics and machine learning study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnti-neutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN) and immunoglobulin G4-related disease (IgG4-RD) are rare autoimmune conditions. Although case reports suggest potential clinical and pathophysiological overlaps, the cross-tissue transcriptional associations between these diseases remain largely unexplored.
methodsWe retrieved the ANCA-GN glomerular dataset (GSE104948) and the IgG4-RD labial salivary gland dataset (GSE40568) from the Gene Expression Omnibus. Differentially expressed genes (DEGs) in ANCA-GN were screened via protein-protein interaction networks, least absolute shrinkage and selection operator regression, and the Boruta algorithm. Given tissue heterogeneity and small IgG4-RD sample size, we used expression trend consistency (log-fold change direction) rather than differential validation to explore shared transcriptional features. Receiver operating characteristic curves assessed discriminative potential. Pathway associations were explored using gene set enrichment analysis, and immune infiltration was evaluated with CIBERSORT, single-sample gene set enrichment analysis, and MCPcounter. Transcription factor-mRNA-microRNA networks were also constructed.
resultsWe identified 305 DEGs (209 upregulated, 96 downregulated) in ANCA-GN, enriched in immune/inflammatory pathways including phosphatidylinositol 3-kinase-Akt and mitogen-activated protein kinase signaling. After machine learning and cross‑trend comparison with IgG4‑RD, ITGAM and CXCL1 were identified as candidate cross‑tissue markers, with ITGAM demonstrating robust predictive performance in both internal and external validation (AUC = 0.921, AUC = 0.844, respectively). CXCL1 showed good internal discrimination (AUC = 0.937) but substantially lower external validity (AUC = 0.622), suggesting limited generalizability. ITGAM therefore emerges as a more reliable cross‑disease biomarker candidate, whereas CXCL1 requires further validation. Both diseases showed increased B‑cell, T‑cell, and monocyte infiltration, but effector profiles differed: neutrophils dominated in ANCA‑GN, while plasma cells/M2 macrophages dominated in IgG4‑RD. Regulatory analysis suggested SPI1 may regulate ITGAM, and CEBPD, NFKB1, and RELA may drive CXCL1 expression under inflammation.
conclusionThis study systematically revealed shared differential expression trends and immune‑related pathway enrichment features between ANCA‑GN and IgG4‑RD at the transcriptomic level, and identified ITGAM and CXCL1 as potential cross‑tissue candidate biomarkers, offering novel insights into the transcriptomic‑level cross‑tissue associations between the two diseases. However, these findings are entirely derived from bioinformatics predictions and require further experimental validation. The low AUC value of CXCL1 in the external validation underscores this need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.